Affinity Asset Advisors, LLC Lian Bio Transaction History

Affinity Asset Advisors, LLC

8 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q4 2023 Feb 13, 2024	BUY	$1.33 - $4.6 $4.13 Million - $14.3 Million	3,107,337 Added 462.16%	3,779,694 $16.9 Million
Q3 2023 Nov 14, 2023	SELL	$1.49 - $2.46 $191,195 - $315,664	-128,319 Reduced 16.03%	672,357 $1 Million
Q2 2023 Aug 14, 2023	BUY	$1.79 - $2.85 $269,710 - $429,426	150,676 Added 23.18%	800,676 $1.83 Million
Q4 2022 Feb 13, 2023	BUY	$1.14 - $2.11 $113,999 - $211,000	100,000 Added 18.18%	650,000 $1.07 Million
Q3 2022 Nov 14, 2022	BUY	$1.87 - $3.0 $187,000 - $300,000	100,000 Added 22.22%	550,000 $1.1 Million

Q2 2022 Aug 12, 2022	BUY	$2.15 - $6.01 $268,750 - $751,250	125,000 Added 38.46%	450,000 $972,000
Q1 2022 May 13, 2022	BUY	$2.8 - $6.21 $707,263 - $1.57 Million	252,594 Added 348.86%	325,000 $1.21 Million
Q4 2021 Feb 11, 2022	BUY	$6.14 - $16.2 $444,572 - $1.17 Million	72,406 New	72,406 $446,000

1.09M

Ticker LIAN
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 108,354,000
Market Cap $32.5M
Description
LianBio, a biopharmaceutical company, engages in developing and commercializing medicines for cardiovascular, oncology, respiratory, opthalmology, and inflammatory diseases in China and other Asian countries. The company develops mavacamten for the treatment of obstructive and non-obstructive hypertrophic cardiomyopathy, and heart failure with p...

Get notified when there are updates to the investment portfolio of Affinity Asset Advisors, LLC, based on Form 13F filings with the SEC.

Stay updated on Affinity Asset Advisors, LLC with notifications on news.